- Home
- About the College
- Governance
- College Committees & Steering Groups
- College Assembly
- College Council
- College Executive Management Committee
- College Academic Programmes and Curriculum Development Committee
- College Graduate Studies Committee
- College Research & Innovation Committee
- College Teaching Learning and Student Experience Committee
- College Student Recruitment and Outreach Committee
- College Sabbatical Research Leave Committee
- College of SEFS Adjunct Appointments Committee
- International Education Committee
- College Postgraduate Student Committee
- Athena SWAN Steering Group
- College Committees & Steering Groups
- Human Resources
- Annual UCC STEM Awards
- Scholarships and Prizes
- Women in STEM Panel Talks
- Inaugural Professorial Lectures
- Athena SWAN in SEFS
- Proposal Calls
- Contact Us
- Science in Society Public Lecture Series
- Governance
- News
- Staff
- Schools and Departments
- Current Students
- Undergraduate Courses
- Postgraduate Courses
- International Students
- Research and Innovation
- Employability and Careers
- Outreach and Public Engagement
- Science Week
- Transition Year Programmes
News 2024
UCC alumni named as EY Entrepreneurs of the Year
UCC alumni Sharon Cunningham (BSc Finance) and Orlaith Ryan (Biological and Chemical Sciences) have been named the 2024 EY Entrepreneurs Of The Year.
In addition to this prestigious honour, Sharon and Orlaith were also recognised as winners in the Emerging Category at this year’s awards.
Their company, Shorla Oncology, headquartered in Clonmel, is making significant strides in the pharmaceutical industry. Shorla Oncology specialises in developing and commercialising innovative oncology drugs for orphan and paediatric cancers. Their mission is to enhance existing oncology treatments through formulation re-innovation, focusing on areas where current treatments are limited, in shortage, or inadequate for the target population.
The company’s portfolio includes four products approved by the U.S. Food and Drug Administration (FDA) and currently on the US market.